Active process to nullify rapidly-grown ‘Eiliquis’ & ‘Pradaxa’ patents
Domestic pharmaceutical companies will challenge the patent wall of novel oral anticoagulants(NOACs), ‘Pradaxa’ and ‘Eliquis.’ They are also trying to nullify the ‘Brilinta’ patent as well.
According to the pharmaceutical industry and the Intellectual Property Tribunal on the 6th, Korean pharmac...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
